A. Yu. Melnyk

A. Yu. Melnyk

Auto-generated profile, based on publicly available information

A. Yu. Melnyk

Національний університет охорони здоров’я України імені П.Л. Шупика, Київ; ДНП «Інститут серця МОЗ України», Київ

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2021 in Економіка та суспільство
Verified
Journal Article
Closed access
PDF file
ОГОльга Гук
Ольга Гук
ОКОлена Кучма
Олена Кучма
АМАнна Мельник
Анна Мельник
Стаття присвячена актуальним питанням застосування інноваційних логістичних процесів для розвитку вітчизняних підприємств. У статті розкрито роль інноваційних логістичних процесів як фактору нарощення ефективності діяльності в контексті інноваційної діяльності. Авторами проаналізовано як розвивалася електронна комерція в період пандемії. Визначено, що обмежувальні заходи негативно вплинули на транспорту логістику. У статті досліджено взаємозв’язок інноваційного розвитку та логістики. Авторами наведено динаміку комерційних рейсів територією ЄС за 2020 рік. У статі досліджено використання повного комплексу логістичних операцій (фулфілмент). Виокремлено проблеми, які виникли перед підприємствами в контексті складської логістики. Розглянуто, яким чином змінилися підходи до методів управління логістикою на підприємствах. Наведено тенденції використання компаніями програмного забезпечення для роботи з ланцюгами поставок та нові можливості зробити логістичні ланцюги прозорими та швидко реагувати на зміни на всіх етапах логістичних процесів. Досліджено використання роботизації складських процесів, що впливає на активний розвиток підприємства та можливість використання цифрових двійників у логістиці. Проаналізовано рейтинг вартості складських приміщень у світі. Досліджено логістичні послуги ТОВ «Сільпо-ФУД», що є частиною однієї з найбільших рітейл груп країни Fozzy Group. Визначено необхідність оптимізації логістичних процесів для забезпечення гнучкості у діяльності підприємств в умовах COVID-19. Авторами запропоновано використання компаніями нових інноваційних логістичних підходів з метою розвитку сучасних підприємств. Окреслено необхідність формування інноваційних рішень, що сприятимуть ефективному використанню інноваційних логістичних процесів та оптимізації логістичної діяльності.

31 August 2025 in Cardiac Surgery and Interventional Cardiology
Verified
Journal Article
Open access
PDF file
AMA. Yu. Melnyk
A. Yu. Melnyk
NYN. O. Yaschenko
N. O. Yaschenko
The aim – to analyze the frequency and structure of complications in patients with refractory chronic heart failure depending on their inclusion on the waiting list for heart transplantation (HT).Materials and methods. A one-center retrospective analysis of 547 cases of patients with end-stage CHF treated between 2021 and 2024 was conducted. Patients were divided into two groups depending on whether they were listed for HT: Group A (n = 464, listed) and Group B (n = 83, not listed due to relative contraindications). Clinical, demographic, echocardiographic, hemodynamic, and laboratory data were analyzed. Results. Patients on the waiting list (Group A) were significantly younger and had a lower NYHA functional class, fewer comorbidities (arterial hypertension, obesity, history of stroke), better echocardiographic parameters (higher LVEF, TAPSE, lower IVC diameter, and LV wall thickness), and more favorable pulmonary hemodynamics compared to non-listed patients. Group A also showed significantly lower rates of repeated hospitalizations (60.1 % vs. 81.9 %, p = 0.001), severe complications such as ventricular arrhythmias, ICD implantation, cardiogenic shock, need for inotropic or mechanical circulatory support, renal replacement therapy, thromboembolic events, and pneumonia. Overall mortality was significantly lower in the listed group (21.1 % vs. 49.4 %, p = 0.001). Conclusions. Inclusion in the heart transplant waiting list is associated with fewer hospitalizations, reduced severe complications, and lower mortality, which is likely related to closer monitoring and advanced medical care in this group.

27 June 2025 in Ukrainian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
AMA. Yu. Melnyk
A. Yu. Melnyk
NYN. O. Yaschenko
N. O. Yaschenko
HKH. I. Kovtun
H. I. Kovtun
IKI. M. Kuzmych
I. M. Kuzmych
SMStepan Maruniak
Stepan Maruniak
BTB. M. Todurov
B. M. Todurov
The aim – to analyze mortality risk factors among patients on the heart transplant waiting list in Ukraine.Materials and methods. The study included 464 patients who were on the HT waiting list at the State Non-Profit Enterprise «Heart Institute of the Ministry of Health of Ukraine» between 2021 and 2024. Demographic parameters, HF etiology, urgency status, laboratory values, use of mechanical circulatory support (MCS), functional test results, and complications were analyzed. One-year survival was predicted using the Seattle Heart Failure Model (SHFM). Statistical analysis included Student’s t-test, Mann-Whitney test, Pearson’s χ2 test, and logistic regression (p<0.05).Results. The mean age of patients was 49 (38; 58) years, with males comprising 82.8 % of the cohort. HT was performed in 89 (19.2 %) patients, with an average waiting time of 222±45 days. During the waiting period, 11 (2.73 %) patients required MCS implantation, 8 (1.72 %) developed pulmonary embolism, 53 (11.4 %) experienced congestive pneumonia, 27 (5.82 %) had a stroke, 48 (10.3 %) developed gastrointestinal bleeding, and 29 (6.25 %) required dialysis. The overall mortality rate was 21.1 % (98 patients). Deceased patients were significantly older (54 (40; 63) years vs. 47 (33; 58) years, p=0.011), more frequently classified as NYHA functional class IV (35.7 % vs. 14.8 %, p=0.0001), and were more likely to have a diagnosis of dilated cardiomyopathy (80.6 % vs. 62.8 %, p=0.005). Blood group AB was more prevalent among deceased patients (8.16 % vs. 1.37 %, p=0.0003), as well as a history of cardiac surgery (19.4 % vs. 9.86 %, p=0.010) and a longer waiting time (291 (147; 672) vs. 204 (101; 494) days, p=0.0011). Additionally, intra-aortic balloon pump support was more frequently used in the deceased group (3.06 % vs. 0.00 %, p=0.008), indicating a more critical condition.Conclusions. The main mortality risk factors among heart transplant waiting list patients in Ukraine include age, NYHA functional class IV, dilated cardiomyopathy, blood group AB, prior cardiac surgery, and longer waiting time.

20 August 2025 in EMERGENCY MEDICINE
Verified
Journal Article
Open access
PDF file
ABA.V. Biliavska
A.V. Biliavska
NYN.O. Yashchenko
N.O. Yashchenko
BTB.M. Todurov
B.M. Todurov
OLO.A. Loskutov
O.A. Loskutov
IKI.M. Kuzmych
I.M. Kuzmych
MMM.H. Melnyk
M.H. Melnyk
Background. Despite advances in surgical technique and immunosuppression, early- and late-onset cardiac complications remain the main limitation to long-term survival after orthotopic heart transplantation (OHT). Locally derived data are especially relevant for Ukraine, where the donor pool is older and metabolic disorders are more prevalent than the International Society for Heart and Lung Transplantation averages. Objective: to determine the frequency of key cardiac complications after OHT in the largest Ukrainian cohort and to establish independent predictors of each of them, paying special attention to the role of metabolic syndrome (MetS) and diabetes mellitus (DM). Materials and methods. We retrospectively analysed 112 adult recipients who underwent isolated OHT between 2019 and 2025 at a single centre. Four endpoints were assessed: primary graft dysfunction (PGD), acute rejection, cardiac allograft vasculopathy (CAV) and clinically significant arrhythmias. Descriptive statistics, univariate tests (, Fisher; t-test or Mann-Whitney) and four separate forced-entry logistic-regression models were applied. Model fit was checked with the Hosmer-Lemeshow test, discrimination with ROC AUC. Results. Median follow-up was 3.7 years (interquartile range 2.1–4.9). Overall incidence: PGD — 33 %, acute rejection — 38 %, CAV — 28 %, arrhythmias — 18 %. PGD: independent predictors: ischaemic time > 240 min (adjusted odds ratio 5.22; 95% confidence interval 1.75–15.5), systolic pulmonary artery pressure (PAPsys) > 50 mmHg (4.81; 1.84–12.5), donor vasoactive-inotropic score (VIS) > 25 (2.50; 0.92–6.81), donor age > 50 years (2.67; 1.02–6.97) and recipient DM (2.27; 0.56–9.25). Acute rejection: recipient age < 30 years (4.40; 1.64–11.8), female sex (3.52; 1.09–11.3), chronic kidney disease (3.49; 1.13–10.7), PAPsys > 50 mmHg (2.24; 0.95–5.30) and DM (2.02; 0.55–7.44). Arrhythmias: donor VIS > 25 (7.33; 2.42–22.2), pre-operative extracorporeal membrane oxygenation/intra-aortic balloon pump (3.59; 1.08–11.9), donor age > 50 years (2.17; 0.71–6.68) and ischaemic time > 240 min (2.07; 0.58–7.34). CAV: prior rejection episodes (13.9; 4.44–43.6), MetS (4.03; 1.21–13.4), donor age > 50 years (3.98; 1.07–14.7), donor VIS > 25 (2.74; 0.78–9.60), DM (4.43; 0.74–26.5) and chronic kidney disease (2.42; 0.57–10.3). Conclusions. Early mechanical complications are primarily driven by donor organ quality and implantation haemodynamics, whereas immune-mediated rejection and CAV reflect a synergy between immunological triggers and recipient metabolic status. MetS and DM act as universal amplifiers of adverse events. Rigo-rous donor selection (younger age, low VIS, ischaemic time < 180 min), aggressive management of pulmonary hypertension, and early metabolic optimisation (HbA1c < 6.5 %, statins, mo-dern antidiabetic agents) could substantially reduce critical cardiac complications and improve long-term graft survival in the Ukrainian transplant population.

3 December 2025 in Cardiac Surgery and Interventional Cardiology
Verified
Journal Article
Open access
ABA. V. Biliavska
A. V. Biliavska
OZO. J. Zharinov
O. J. Zharinov
AMA. Yu. Melnyk
A. Yu. Melnyk
MLMirko Ljubo Lipovac
Mirko Ljubo Lipovac
YSYa. V. Skybchyk
Ya. V. Skybchyk
HKH. I. Kovtun
H. I. Kovtun
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetically determined myocardial disease characterized by progressive replacement of cardiomyocytes with fibrofatty tissue, predominantly affecting the right ventricle. The condition is associated with malignant ventricular arrhythmias, heart failure, and a high risk of sudden cardiac death.Case Presentation. We present a 12‑year longitudinal follow‑up of a male patient diagnosed with ARVC, who underwent a full therapeutic pathway from antiarrhythmic drug therapy and implantable cardioverter‑defibrillator (ICD) implantation to orthotopic heart transplantation. Initially, the combination of amiodarone, beta‑blocker, and comprehensive quadruple heart failure therapy provided partial control of arrhythmic episodes. However, the disease progressed to biventricular failure accompanied by repeated ICD shocks despite optimal medical treatment.The patient was enrolled on the heart transplantation waiting list and subsequently underwent successful transplantation in 2024. The postoperative course was uneventful with stable graft function. The patient achieved complete structural and functional recovery of the transplanted myocardium under a standard triple immunosuppressive regimen including methylprednisolone, tacrolimus, and mycophenolate mofetil.Conclusions. This case highlights the progressive nature of ARVC and emphasizes the importance of early recognition of the disease, timely ICD implantation for prevention of sudden cardiac death, and heart transplantation as a life‑saving therapy in end‑stage disease. Individualized, multidisciplinary management remains essential for improving long‑term survival and quality of life in patients with ARVC.